![Class 1 PI3K Clinical Candidates and Recent Inhibitor Design Strategies: A Medicinal Chemistry Perspective | Journal of Medicinal Chemistry Class 1 PI3K Clinical Candidates and Recent Inhibitor Design Strategies: A Medicinal Chemistry Perspective | Journal of Medicinal Chemistry](https://pubs.acs.org/cms/10.1021/acs.jmedchem.8b01492/asset/images/large/jm-2018-01492k_0019.jpeg)
Class 1 PI3K Clinical Candidates and Recent Inhibitor Design Strategies: A Medicinal Chemistry Perspective | Journal of Medicinal Chemistry
![CD49d promotes disease progression in chronic lymphocytic leukemia: new insights from CD49d bimodal expression - ScienceDirect CD49d promotes disease progression in chronic lymphocytic leukemia: new insights from CD49d bimodal expression - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0006497120621176-gr1.jpg)
CD49d promotes disease progression in chronic lymphocytic leukemia: new insights from CD49d bimodal expression - ScienceDirect
![CD49d promotes disease progression in chronic lymphocytic leukemia: new insights from CD49d bimodal expression - ScienceDirect CD49d promotes disease progression in chronic lymphocytic leukemia: new insights from CD49d bimodal expression - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0006497120621176-fx1ab.jpg)
CD49d promotes disease progression in chronic lymphocytic leukemia: new insights from CD49d bimodal expression - ScienceDirect
![Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas | Chemical Reviews Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas | Chemical Reviews](https://pubs.acs.org/cms/10.1021/acs.chemrev.5b00392/asset/images/medium/cr-2015-00392a_0003.gif)
Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas | Chemical Reviews
![CD49d promotes disease progression in chronic lymphocytic leukemia: new insights from CD49d bimodal expression - ScienceDirect CD49d promotes disease progression in chronic lymphocytic leukemia: new insights from CD49d bimodal expression - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0006497120621176-gr3.jpg)